Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?
Menée en Suède à partir de données portant sur 196 patients atteints d'un cancer du poumon non à petites cellules de stade avancé recevant des inhibiteurs de points de contrôle immunitaire, cette étude rétrospective analyse l'effet, sur la survie globale et sur la survenue d'événements indésirables induits par les traitements anticancéreux, d'une utilisation de corticoïdes (prednisolone)
The introduction of anti-programmed cell death 1 (PD-1) or programmed death-ligand1 (PD-L1) checkpoint inhibitors has fundamentally changed the standard of care formost patients with metastatic non–small cell lung cancer (NSCLC). It has also providedthe first survival increment in extensive disease small-cell lung cancer (SCLC) formore than two decades. A common aim of these immune modulating agents is to reinvigoratethe host's immune response which has been shut down by various cancer-mediated mechanisms.Accordingly, a major clinical concern relates to the potential of immunosuppressiveagents including corticosteroids to interfere with the activation and maintenanceof anticancer immunity.
European Journal of Cancer , éditorial, 2020